Verastem CFO sells $90,592 in stock

Verastem (VSTM) CFO Daniel Calkins sold 11,143 shares at $8.13 on May 20th for tax obligations after acquiring 38,850 shares from vested RSUs tied to the FDA approval of its avutometinib and defactinib combination therapy for low-grade serous ovarian cancer. This follows a period where VSTM shares have surged over 110% in six months, driven by the FDA approval and a $75 million private placement to support the launch and advance VS-7375. Jefferies raised its price target to $19, while Mizuho maintained an Outperform rating with an $8 target.

Analysis

Verastem, Inc. (NASDAQ:VSTM) has experienced significant positive developments, anchored by the early FDA approval of its combination therapy, avutometinib and defactinib, for recurrent KRAS mutant low-grade serous ovarian cancer. This approval, ahead of the PDUFA date, catalyzed a surge in its stock price, which has risen over 110% in the past six months. Concurrently, Chief Financial Officer Daniel Calkins sold 11,143 shares at $8.13 each, totaling $90,592, a transaction explicitly stated to cover tax obligations from 38,850 vested performance-based RSUs linked to the FDA approval; Calkins retains 114,055 shares. To support the commercial launch and further research, including the advancement of its KRAS G12D inhibitor VS-7375 (IND cleared for a Phase 1/2a study in mid-2025), Verastem secured $75 million via a private placement. Analyst sentiment is largely positive: Jefferies raised its price target to $19 maintaining a Buy rating, while Mizuho maintained an Outperform rating with an $8 target. InvestingPro analysis suggests the stock, with a market capitalization of $438 million, may be trading below its fair value, despite not being a top ProPicks AI selection, with analyst price targets generally ranging from $13 to $20.

Key Decisions for Investors

• Investors should closely monitor the commercial uptake and revenue generation from Verastem's newly FDA-approved ovarian cancer therapy, as this will be a key driver of near-term performance.
• The progression of VS-7375 through its Phase 1/2a trial, expected to initiate mid-2025, represents a significant pipeline catalyst; any positive interim data could further de-risk the company's long-term growth prospects.
• Given the stock's substantial recent appreciation alongside positive catalysts and analyst outlooks, investors might consider the current valuation in light of InvestingPro's fair value assessment, while remaining cognizant of inherent biotech sector volatility and the specific context of the CFO's tax-related share sale.